(AOF) – Genoway announces a net profit of 1 million euros for the first half, an increase of 406% year-on-year. The biotech specializing in the design of predictive preclinical solutions shows EBITDA growth of 70% to 2.33 million euros for turnover up 20% to 9.33 million euros. It forecasts that this growth should continue in the second half of the year with the aim of exceeding the threshold of 20 million euros in 2023.
“We are particularly proud to have achieved 18 months in advance the profitability objective that we set for ourselves almost 5 years ago by initiating our new strategic plan focused on the development of a range of proprietary catalog models in immuno-oncology”, declares Alexandre Fraichard, Managing Director.
“In 4 years, we have already doubled our turnover and gone from negative EBITDA to an EBITDA margin of 25%, which benefits both from the strong profitability of our Catalog model offering but also the progress made by the Genoway teams in terms of industrial performance.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
